" A scientist advocates the revival of an antiviral cancer treatment popular in the 1980s. Cummins, a microbiologist and veterinarian, has produced an astute, thought-provoking, and convincing testament to the revitalization of low-dose interferon administration. The goal of his book--written with former attorney Heckenlively--is to renew clinical and public interest in the drug, which came into prominence in the early '80s. Despite proven antiviral and anti-cancer properties in animals, the treatment failed to surpass the scientific community's lofty expectations for it in human trials. Cummins, whose narrative perspective predominantly anchors the work, first charts his own interest and history in veterinary medicine and how his distinguished career in immunological research science prepared him to become a leading voice in interferon application advocacy for animals as well as humans. The volume describes interferon as a naturally occurring protein found in the human body during a viral infection that has been resoundingly beneficial for animals in veterinary arenas as well as helpful in providing broad protection to humans by shortening the duration of viral shedding. Although early Japanese and Russian studies bolstered low-dose interferon as an influenza prophylaxis, its widespread usage never materialized. Cummins embarked on a career researching oral human interferon and authoring many articles on its efficacy in trials.

This study-heavy work shares the wealth of more than five decades of research backing interferon's use, including controversial success stories, like a veterinarian who treated himself with the drug after contracting HIV; case studies with compromised patients; and media coverage. Parts of the narrative utilize scientific jargon that may confuse some lay readers, though others will find themselves persuaded by the sensible and science-supported arguments. Concluding chapters offer an update on the current state of more recent clinical trials and an enlightening lesson on viral behavior and how the immune system's reaction to classic coronaviruses could prepare the human body's defense mechanisms against SARS-CoV-2. Cummins gets personal in the closing pages, admitting to suffering from Parkinson's disease and planning to relinquish his participation in the effort to reawaken interest in interferon usage. He asserts that interferon has its share of detractors who believe the drug "threatens to upend the pharmaceutical bottom line." Sound research and expert experience create an illuminating work on the potential benefits of interferon." -- Kirkus Reviews "The Case For Interferon by Dr. Joseph Cummins and Kent Heckenlively, JD, was filled with more surprises than there are ways for a farmer to go to town.

Those surprises start with a stunning foreword by Dr. Judy Mikovits, which adds perspective to many of the questions Dr. Cummins raises in this page-burning read. Interferon, a naturally occurring protein, long utilized very successfully in veterinary medicine, has been ignored for the most part by researchers and medical doctors for human use. Cummins believes that disinterest was based on faulty original research where huge amounts of interferon produced poor effects, when only very small amounts of the substance occurs in nature. This book builds an inescapably strong case for low-dose interferon to be re-visited for its potential value to human immune systems and overall health." -- Max Swafford , author, editor, educator.